MedTrace Logo

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

NCT00955630 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.

Conditions

  • Ocular Histoplasmosis Syndrome

Interventions

DRUG

ranibizumab

3 monthly injections of ranibizumab followed by prn injections for the remainder of the study

DRUG

ranibizumab

prn injections of ranibizumab throughout the study

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retina Associates of Kentucky

    lead OTHER

Principal Investigators

  • John Kitchens, MD · Retina Associates of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955630 on ClinicalTrials.gov